Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Recommendation of “Buy” by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received an average rating of “Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $36.60.

KNSA has been the subject of several recent research reports. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Evercore ISI boosted their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday.

Kiniksa Pharmaceuticals Price Performance

KNSA stock opened at $23.03 on Friday. Kiniksa Pharmaceuticals has a 1 year low of $14.12 and a 1 year high of $28.15. The firm has a 50-day moving average of $25.11 and a 200 day moving average of $22.61. The company has a market cap of $1.64 billion, a P/E ratio of -164.50 and a beta of 0.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s revenue was up 67.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.20) EPS. On average, equities research analysts expect that Kiniksa Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the sale, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the sale, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 112,692 shares of company stock worth $2,950,315 in the last quarter. Corporate insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Allspring Global Investments Holdings LLC increased its position in shares of Kiniksa Pharmaceuticals by 18.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 61,106 shares of the company’s stock valued at $1,206,000 after purchasing an additional 9,490 shares during the last quarter. Principal Financial Group Inc. grew its position in Kiniksa Pharmaceuticals by 42.7% during the first quarter. Principal Financial Group Inc. now owns 58,991 shares of the company’s stock valued at $1,164,000 after buying an additional 17,659 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Kiniksa Pharmaceuticals by 5.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock valued at $413,000 after buying an additional 1,153 shares during the period. Janney Montgomery Scott LLC increased its holdings in Kiniksa Pharmaceuticals by 7.8% during the first quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company’s stock valued at $530,000 after buying an additional 1,940 shares during the last quarter. Finally, Nordea Investment Management AB bought a new position in Kiniksa Pharmaceuticals in the first quarter worth approximately $2,487,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.